Can-Fite BioPharma's Namodenoson Drug Gets Australian Patent Allowance
Ticker: CANF · Form: 6-K · Filed: Nov 4, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Nov 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent, pharmaceutical, intellectual-property
TL;DR
Can-Fite BioPharma just got an Australian patent allowance for their anti-obesity drug Namodenoson. Big win for IP!
AI Summary
Can-Fite BioPharma Ltd. announced on November 4, 2024, that its anti-obesity drug, Namodenoson, has received a patent allowance in Australia. This development is a significant step for the company's intellectual property portfolio and potential commercialization of the drug.
Why It Matters
This patent allowance in Australia strengthens Can-Fite BioPharma's intellectual property protection for Namodenoson, potentially paving the way for future market exclusivity and commercial opportunities.
Risk Assessment
Risk Level: low — The filing is a routine report of a patent allowance, which is generally positive news with limited immediate downside risk.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — The company filing the report and owner of the drug.
- Namodenoson (drug) — The anti-obesity drug that received patent allowance.
- Australia (country) — The jurisdiction where the patent allowance was granted.
- November 4, 2024 (date) — The date of the press release announcing the patent allowance.
FAQ
What is the significance of the patent allowance for Namodenoson in Australia?
The patent allowance in Australia strengthens Can-Fite BioPharma's intellectual property protection for Namodenoson, potentially leading to market exclusivity and commercial opportunities.
When was the press release announcing this patent allowance issued?
The press release was issued on November 4, 2024.
What is the primary indication for the drug Namodenoson?
Namodenoson is described as an anti-obesity drug.
Which exhibit contains the press release regarding the patent allowance?
The press release is furnished as Exhibit 99.1.
What is the principal executive office address for Can-Fite BioPharma Ltd.?
The principal executive offices are located at 26 Ben Gurion Street, Ramat Gan, 5257346, Israel.
Filing Stats: 187 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2024-11-04 07:09:45
Filing Documents
- ea0219808-6k_canfite.htm (6-K) — 9KB
- ea021980801ex99-1_canfite.htm (EX-99.1) — 15KB
- 0001213900-24-093742.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: November 4, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 2